Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
3.370
-0.355 (-9.53%)
Mar 9, 2026, 2:03 PM EDT - Market open
Aditxt Employees
Aditxt had 26 employees as of December 31, 2024. The number of employees decreased by 21 or -44.68% compared to the previous year.
Employees
26
Change (1Y)
-21
Growth (1Y)
-44.68%
Revenue / Employee
$229
Profits / Employee
-$1,624,583
Market Cap
748.15K
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Lyra Therapeutics | 30 |
| Virax Biolabs Group | 19 |
| Reviva Pharmaceuticals Holdings | 14 |
| Biodexa Pharmaceuticals | 13 |
| Ensysce Biosciences | 8 |
| CDT Equity | 6 |
| Onconetix | 5 |
| CNS Pharmaceuticals | 5 |
ADTX News
- 4 days ago - Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026 - Business Wire
- 3 months ago - Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing - Business Wire
- 4 months ago - Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025 - Business Wire
- 4 months ago - Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market - Business Wire
- 4 months ago - Evofem Announces Voting Results from Special Meeting of Stockholders - PRNewsWire
- 6 months ago - Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms - PRNewsWire
- 6 months ago - Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting - PRNewsWire
- 7 months ago - Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030 - Business Wire